Obagi Nu-Derm Clear Fx is a professional-strength, hydroquinone-free skin-brightening cream designed to improve the appearance of dark spots, hyperpigmentation, and uneven skin tone. It is part of the Nu-Derm Fx System, which works at the cellular level to promote a more even, radiant, and healthier-looking complexion.
Key Features and Benefits
- Brightening Agent: Formulated with 7% Arbutin, a natural, “nature-identical” skin-brightening agent that inhibits tyrosinase activity to reduce the production of excess melanin.
- Targeted Treatment: Specifically targets dark spots, age spots, sun damage, and melasma.
- Antioxidant Support: Includes antioxidants to protect the skin against environmental stressors and support a more resilient complexion.
- Hydroquinone-Free: Provides a safer alternative for long-term use or for individuals looking to avoid hydroquinone.
- Suitable for All Skin Types: Formulated for various skin types, including normal to oily, normal to dry, and combination.
Main Ingredients
- 7% Arbutin: Minimizes dark spots and evens skin tone.
- Antioxidants: Help maintain skin vitality.
- Vitamin C (Ascorbic Acid): Promotes collagen production and fights free radicals.
- Vitamin E: Protects against free radicals and signs of aging.
How to Use
- Application: Apply to the face twice daily (morning and evening) after cleansing and toning.
- Routine: It is best used as part of the complete Obagi Nu-Derm Fx System.
- Sun Protection: Because the product encourages cell turnover, daily sunscreen application is essential to prevent further pigmentation.
- Results: Visible improvements typically appear within 4-6 weeks of consistent use, with optimal results in 16-20 weeks.
Important Notes:
- This product is for external use only.
- Consult a physician or dermatologist to determine if it is suitable for your skin type, especially if you are pregnant or nursing.
- Some initial redness, dryness, or flaking may occur, which is common with this type of treatment.
No products in the cart.
Reviews
There are no reviews yet.